Elder Pharmaceuticals, a leading pharmaceuticals company in India, having consolidated turnover in excess of Rs 1,350 crore for FY12 and ranked 27 amongst Indian pharmaceutical companies as per IMS Report October 2012, has agreed to establish a Joint Venture Company (JVC) with KOSE Corporation (KOSE) with the provisional name of KOSE Elder (India).
On March 6, 2013 both the companies have, subject to the fulfillment of certain terms and conditions finalized terms and conditions of the joint venture contract. The agreement stipulates that KOSE will focus on the Indian market, through the JVC for manufacturing and selling cosmetics in India. KOSE will hold 60% and Elder to hold 40% in the proposed JV. Elder has successfully established and run subsidiaries abroad and with alliance with KOSE, Elder is foraying into its maiden joint Venture arrangement in India with a Japanese company.
KOSE’s key means of advancing into overseas markets up to now has been to export from Japan only those of its existing brand products that matched the requirements of the target country’s market, but in India, where culture and tastes are very different, they have considered it essential to undertake strategic and business planning tailored to the region, and are proceeding with investigations through agreements with local enterprises that are familiar with the markets.
Elder Pharmaceuticals (EPL) has around six manufacturing units in India, all as per international standards. Post increasing its stake in Elder Biomeda AD and Neutrahealth PLC, EPL also has access to the manufacturing units of these companies in Bulgaria and Birmingham, UK respectively coupled with distribution network and brands of the same.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: